ARGENX SE's ticker is ARGX and the CUSIP is 04016X101. A total of 290 filers reported holding ARGENX SE in Q2 2023. The put-call ratio across all filers is 1.54 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,815,860 | +8.0% | 22,000 | -14.4% | 5.89% | +11.4% |
| Q2 2023 | $10,016,061 | +4.6% | 25,700 | 0.0% | 5.29% | -9.7% |
| Q1 2023 | $9,575,310 | +1.1% | 25,700 | +2.8% | 5.86% | -8.4% |
| Q4 2022 | $9,470,750 | +7.3% | 25,000 | 0.0% | 6.40% | +12.3% |
| Q3 2022 | $8,826,000 | -6.8% | 25,000 | 0.0% | 5.70% | +1.1% |
| Q2 2022 | $9,472,000 | +20.2% | 25,000 | 0.0% | 5.64% | +63.3% |
| Q1 2022 | $7,883,000 | -10.0% | 25,000 | 0.0% | 3.45% | -2.7% |
| Q4 2021 | $8,755,000 | +16.0% | 25,000 | 0.0% | 3.55% | +6.5% |
| Q3 2021 | $7,550,000 | +25.4% | 25,000 | +25.0% | 3.33% | +56.3% |
| Q2 2021 | $6,021,000 | -8.9% | 20,000 | -16.7% | 2.13% | -25.8% |
| Q1 2021 | $6,609,000 | -6.4% | 24,000 | 0.0% | 2.87% | -1.3% |
| Q4 2020 | $7,058,000 | +12.0% | 24,000 | 0.0% | 2.91% | -9.6% |
| Q3 2020 | $6,300,000 | +16.5% | 24,000 | 0.0% | 3.22% | +6.5% |
| Q2 2020 | $5,406,000 | +71.0% | 24,000 | 0.0% | 3.02% | +46.2% |
| Q1 2020 | $3,162,000 | -10.5% | 24,000 | +9.1% | 2.07% | -7.5% |
| Q4 2019 | $3,531,000 | – | 22,000 | – | 2.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SAL Trading, LLC | 36,100 | $17,747,843 | 24.88% |
| Artia Global Partners LP | 49,238 | $24,206,878 | 10.06% |
| Paradigm Biocapital Advisors LP | 261,443 | $128,533,222 | 8.72% |
| Darwin Global Management, Ltd. | 45,615 | $22,425,702 | 7.89% |
| Avoro Capital Advisors LLC | 1,000,000 | $491,630,000 | 7.67% |
| Bellevue Group AG | 911,530 | $448,135,494 | 7.22% |
| Eagle Health Investments LP | 64,400 | $31,660,972 | 6.98% |
| DCF Advisers, LLC | 22,000 | $10,815,860 | 5.89% |
| SAL Trading, LLC | 8,149 | $4,006,293 | 5.62% |
| RTW INVESTMENTS, LP | 507,195 | $249,352,278 | 5.26% |